Most Read Articles
Tristan Manalac, 6 days ago
Atopic dermatitis appears to impair sleep quality, but not sleep duration, in children, particularly in those with more severe diseases, according to a new study.
13 Mar 2019
Individuals following a diet low in or free of meat are at lower risk of diabetes, and this protective association is partly attributable to having a lower body mass index when compared with regular meat eaters, according to a study.
4 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
13 Mar 2019
Vitamin E supplementation does not appear to contribute to blood pressure (BP) improvement, with results of a recent systematic review and meta-analysis showing decreases only in systolic (S)BP but no favourable effect on diastolic (D)BP and mean arterial pressure (MAP).

Apixaban trumps standard treatment in preventing cancer-associated VTE recurrence

Pearl Toh
07 Dec 2018

Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

“Nearly one in five patients with cancer will develop a clot in the veins … Clotting events can be deadly, with pulmonary embolism being the second most common cause of death in [patients with] cancer,” said Dr Robert McBane from the Mayo Clinic in Rochester, Minnesota, US.

The current guideline-recommended treatment for cancer-associated VTE is LMWH, but LMWH injections are expensive and can cause bruising and pain at the injection site, said McBane. “Patients [with cancer] may experience low platelet counts and be at risk for a clotting disorder called heparin-induced thrombocytopenia.” Also, kidney injury induced by cancer therapy can further limit the use of LMWH.  

Compared with the LMWH dalteparin, apixaban significantly reduced the risk of recurrent VTE in cancer patients by 90.1 percent (hazard ratio [HR], 0.099; p=0.03), with VTE recurrence observed in 0.7 percent of apixaban-treated patients vs 6.3 percent in the dalteparin group. [ASH 2018, abstract 421]

Major bleeding rates were comparable between the apixaban and dalteparin groups (0 percent vs 1.4 percent; p=0.14), indicating that apixaban is safe. Major plus clinically relevant nonmajor bleeds also occurred at similar rates in both groups (6.2 percent vs 6.3 percent; p=0.88).

There were no significant differences in mortality rates at 6 months between the two groups (HR, 1.40; p=0.31).

Based on monthly quality-of-life surveys, patients showed that they preferred apixaban over dalteparin when considering burden of delivery, concerns for excess bruising, irritation, stress, and overall satisfaction with anticoagulants (p<0.05).

“Apixaban was well tolerated with superior patient satisfaction and significantly fewer study drug discontinuations compared with dalteparin,” said McBane, who noted that more patients in the dalteparin group discontinued treatment compared with the apixaban group (15 percent vs 4 percent; p=0.0012). “These data support the use of apixaban for the acute treatment of cancer-associated VTE.”

The multicentre, open-label trial randomized 287 patients (mean age, 64 years) with cancer in a 1:1 ratio to receive apixaban twice daily (10 mg for 7 days followed by 5 mg dose) or subcutaneous dalteparin (200 IU/kg for 1 month and subsequently 150 IU/kg once daily) for 6 months. About two-third of the patients (65.5 percent) had metastatic disease, with lung, pancreas, colorectal, and breast cancers being the four most prevalent cancer types.

“As a class, [direct oral anticoagulants] have a number of advantages, including oral delivery, lack of interactions with foods or other medications, and the lack of a need for monitoring drug levels,” said McBane.

“We are hopeful that this medication will also improve medication compliance in patients [with cancer] requiring blood thinner therapy,” he added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 6 days ago
Atopic dermatitis appears to impair sleep quality, but not sleep duration, in children, particularly in those with more severe diseases, according to a new study.
13 Mar 2019
Individuals following a diet low in or free of meat are at lower risk of diabetes, and this protective association is partly attributable to having a lower body mass index when compared with regular meat eaters, according to a study.
4 days ago
Drinking coffee confers benefits for recurrence of hepatocellular carcinoma (HCC) and survival following orthotopic liver transplantation, a study has found.
13 Mar 2019
Vitamin E supplementation does not appear to contribute to blood pressure (BP) improvement, with results of a recent systematic review and meta-analysis showing decreases only in systolic (S)BP but no favourable effect on diastolic (D)BP and mean arterial pressure (MAP).